Dr. Claudia Krieger-Grübel
Gastroenterology/Hepatology · Dept. I
VedolizumAb in IBD - Real-world non-Interventional, ProspEctive, ObservaTional StudY to describe real-world treatment patterns in patients on vedolizumab treatment
Jul 14, 2022This is a non-interventional prospective observational study in patients receiving Vedolizumab therapy for IBD. Sites will enroll patients with moderately to severely active IBD (UC or CD), initiating or ongoing IV induction treatment with vedolizu...
Clinical Studies - Jul 14, 2022 - Dec 31, 2023
Automatically Closed
Project leader: Brand Stephan
Members: Eckhold Annika, König Marius, Krieger-Grübel Claudia
I6T-MC-AMAX
Jun 7, 2022A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Crohn's Disease
Clinical Studies - Jun 7, 2022 - Dec 31, 2024
Ongoing
Project leader: Brand Stephan
Members: Eckhold Annika, Krieger-Grübel Claudia, König Marius
CDED Ernährungsstudie
Jun 1, 2022The Crohn’s disease exclusion diet (CDED) for induction and maintenance of remission in Crohn’s patients with or without additional medical therapy. An open label observational trial
Clinical Studies - Jun 1, 2022 - Dec 30, 2023
Automatically Closed
Project leader: Krieger-Grübel Claudia
Members: Brand Stephan, Eckhold Annika
CED-4/CEL
Jun 1, 2022This is a double-blind, randomised, multicentre, placebo-controlled, comparative phase IIb dose-finding and efficacy trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to compare...
Clinical Studies - Jun 1, 2022 - Dec 31, 2024
Ongoing
Project leader: Brand Stephan
Members: Eckhold Annika, König Marius, Krieger-Grübel Claudia, Truniger Samuel
Amgen Efavaleukin Alfa
Apr 25, 2022A Phase 2, Multicenter, Dose-finding, Double blinded, Pla-cebo- Controlled Study to Evaluate the Safety and Effi-cacy of Efavaleukin Alfa Induc-tion Therapy in Patients with Mederatly to Severely UC
Clinical Studies - Apr 25, 2022 - Dec 31, 2023
Automatically Closed
Project leader: Brand Stephan
Members: Eckhold Annika, Krieger-Grübel Claudia
Analysis of the effect of biological therapy on SARS-CoV-2-specific antibody levels following booster vaccination in patients with inflammatory bowel disease
Jan 20, 2022This is a national multi-center cohort confirmatory study which is designed as a prospective observational trial combined with retrospective data collection. Prospective data are collected through a patient questionnaire and assessment of blood sam...
Clinical Studies - Jan 20, 2022 - Mar 30, 2023
Automatically Closed
Project leader: Brand Stephan
Members: König Marius, Dütschler Joel, Krieger-Grübel Claudia, Eckhold Annika, Truniger Samuel, Frei Nicola Fabian, Albrich Werner
I6T-MC-AMBI
Feb 1, 2021A Phase 3b, Randomized, Double-Blind, Parallel-Arm, Placebo- and Active- Controlled Treat-Through Study of Mirikizumab and Vedolizumab in participants with Moderately to Severely Active Ulcerative Colitis
Clinical Studies - Feb 1, 2021 - Jan 1, 2024
Completed
Project leader: Brand Stephan
Members: Smolders Jolijn, Krieger-Grübel Claudia
I6T-MC-AMAP
Jan 29, 2021A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 3
Clinical Studies - Jan 29, 2021 - Dec 1, 2024
Ongoing
Project leader: Brand Stephan
Members: Krieger-Grübel Claudia, Smolders Jolijn
M14-675
Jan 1, 2019A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Colitis
Clinical Studies - Jan 1, 2019 - Aug 1, 2020
Completed
Project leader: Sulz Michael
Members: Brand Stephan, Krieger-Grübel Claudia, Smolders Jolijn
I6T-MC-AMAM
Jan 1, 2019A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease
Clinical Studies - Jan 1, 2019 - Dec 1, 2022
Automatically Closed
Project leader: Brand Stephan
Members: Sulz Michael, Smolders Jolijn, Krieger-Grübel Claudia
I6T-MC-AMAN
Jan 1, 2018A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 1
Clinical Studies - Jan 1, 2018 - Feb 1, 2021
Completed
Project leader: Brand Stephan
Members: Krieger-Grübel Claudia, Sulz Michael, Smolders Jolijn
I6T-MC-AMBG
Jan 1, 2018A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 2
Clinical Studies - Jan 1, 2018 - Jun 1, 2021
Automatically Closed
Project leader: Brand Stephan
Members: Sulz Michael, Krieger-Grübel Claudia, Smolders Jolijn
ACRE
Jan 1, 2018A MULTICENTER, MULTI-NATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, PHASE IIA STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF AN ANTHOCYANIN RICH EXTRACT (ACRE) IN PATIENTS WITH ULCERATIVE COLITIS.
Clinical Studies - Jan 1, 2018 - Jul 1, 2021
Completed
Project leader: Brand Stephan
Members: Stillhard Roman, Sulz Michael, Krieger-Grübel Claudia, Smolders Jolijn
Amiselimod
Jun 1, 2017A Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study of Amiselimod (MT-1303) in the Induction and Maintenance of Clinical Response and Remission in Subjects With Moderate to Severe Ulcerative Colitis
Clinical Studies - Jun 1, 2017 - Sep 27, 2022
Automatically Closed
Members: Knellwolf Christina, Dora Barbara, Krieger-Grübel Claudia, Sulz Michael
Mongersen GED-0301
Dec 1, 2016A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of mongersen (GED-0301) for the treatment of subjects with active Crohn’s disease.
Clinical Studies - Dec 1, 2016 - Dec 1, 2018
Completed
Members: Dora Barbara, Knellwolf Christina, Krieger-Grübel Claudia, Sulz Michael
PCG-4/UCR
Dec 1, 2016Randomized, double-blind, double-dummy, placebo-controlled, Phase III clinical trial on the efficacy and safety of a 48-weeks treatment with gastroresistant phosphatidylcholine (LT-02) versus placebo versus mesalamine for maintenance of remission in...
Clinical Studies - Dec 1, 2016 - Dec 1, 2018
Completed
Members: Dora Barbara, Knellwolf Christina, Krieger-Grübel Claudia, Sulz Michael
Abbvie M14-234
Dec 1, 2016A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
Clinical Studies - Dec 1, 2016 - Dec 1, 2018
Automatically Closed
Members: Dora Barbara, Knellwolf Christina, Krieger-Grübel Claudia, Sulz Michael
Entyvio PASS Study
Jul 28, 2016Entyvio (vedolizumab) long-term safety study: An international observational prospective cohort study comparing vedolizumab to other biologic agents in patients with ulcerative colitis or Crohn’s Disease. This is a prospective, observational, multi-...
Clinical Studies - Jul 28, 2016 - Jun 28, 2022
Automatically Closed
Project leader: Brand Stephan
Members: Dora Barbara, Knellwolf Christina, Sulz Michael, Krieger-Grübel Claudia
PCG-2/UCA
Mar 1, 2016Randomized, double-blind, double-dummy, placebo-controlled, Phase III clinical trial on the efficacy and safety of a 12-weeks add-on treatment with LT-02 (gastro-resistant phosphatidylcholine granules) vs. placebo in patients with ulcerative colitis...
Clinical Studies - Mar 1, 2016 - Dec 31, 2017
Aborted
Members: Dora Barbara, Knellwolf Christina, Sulz Michael, Krieger-Grübel Claudia
Eine explorative, randomisierte, placebokontrollierte, doppelblinde Studie mit parallelen Gruppen zur Untersuchung der pharmakodynamischen Wirkung von M0003 auf Reflux-Parameter bei Teilnehmern mit gastroösophagealem Reflux und persistierenden Symptomen trotz Einnahme einer stabilen Dosis eines Protonenpumpenhemmers
May 1, 2011Gastroösophageale Refluxerkrankung (GERD) mit persistierenden Symptomen (d. h. Sodbrennen und Regurgitation) trotz Einnahme einer stabilen Dosis eines Protonenpumpenhemmers (PPI). M0003 wird als mögliche Behandlung für gastroösophagealen Reflux (GE...
Clinical Studies - May 1, 2011 - Sep 30, 2011
Automatically Closed
Project leader: Borovicka Jan
Members: Krieger-Grübel Claudia, Künzler-Heule Patrizia